We are live on ! Find out more
PMVP icon

PMV Pharmaceuticals
PMVP

92 hedge funds and large institutions have $1.31B invested in PMV Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

8% more funds holding

Funds holding: 85 → 92 (+7)

3.31% more ownership

Funds ownership: 93.82% → 97.13% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

9% less capital invested

Capital invested by funds: $1.44B → $1.31B (-$132M)

Holders
92
Holders Change
+7
Holders Change %
+8.24%
% of All Funds
1.61%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
14
Increased
34
Reduced
27
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$38.1M
2
ACA
Avoro Capital Advisors
New York
+$35.1M
3
State Street
State Street
Massachusetts
+$26.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$13.1M
5
RI
RTW Investments
New York
+$10.4M

Top Sellers

Rank Fund Capital Flow
1
EC
Euclidean Capital
New York
-$36.4M
2
IVM
InterWest Venture Management
California
-$35.1M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$33.1M
4
PA
Perceptive Advisors
New York
-$14.2M
5
Franklin Resources
Franklin Resources
California
-$7.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHS
26
PFM Health Sciences
California
$8.59M – – –
Northern Trust
27
Northern Trust
Illinois
$7.54M -$206K -6,439 -2%
Federated Hermes
28
Federated Hermes
Pennsylvania
$7.45M – – –
SFM
29
Sphera Funds Management
Israel
$5.68M +$3.4M +106,451 +127%
Charles Schwab
30
Charles Schwab
California
$5.58M +$2.33M +72,875 +64%
UBS AM
31
UBS AM
Illinois
$5.55M -$175K -5,475 -3%
Invesco
32
Invesco
Georgia
$5.15M -$1.42M -44,538 -20%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$4.52M +$4.85M +151,778 New
FAM
34
Fred Alger Management
New York
$3.73M +$4M +125,211 New
CC
35
Commodore Capital
New York
$3.73M – – –
N
36
Nuveen
North Carolina
$3.2M +$187K +5,865 +6%
ACM
37
Asymmetry Capital Management
California
$3.01M -$28.5K -894 -0.9%
OCA
38
Octagon Capital Advisors
New York
$2.98M -$4.78M -149,859 -60%
UBS Group
39
UBS Group
Switzerland
$2.86M +$3.03M +94,956 +8,776%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$2.37M +$1.43M +44,735 +129%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$2.31M +$372K +11,666 +18%
Deutsche Bank
42
Deutsche Bank
Germany
$1.77M -$15.5K -484 -0.8%
Assenagon Asset Management
43
Assenagon Asset Management
Luxembourg
$1.7M -$3.43M -107,526 -65%
Voloridge Investment Management
44
Voloridge Investment Management
Florida
$1.62M +$1.4M +43,739 +410%
Citigroup
45
Citigroup
New York
$1.61M +$13K +406 +0.8%
Adage Capital Partners
46
Adage Capital Partners
Massachusetts
$1.58M – – –
Prudential Financial
47
Prudential Financial
New Jersey
$1.54M +$573K +17,950 +53%
EC
48
EcoR1 Capital
California
$1.49M – – –
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$1.22M +$924K +28,948 +239%
HS
50
HighVista Strategies
Massachusetts
$1.19M +$511K +16,019 +67%
1
2
3 4

PMVP Hedge Fund Activity: Q3 2021 in Review

92 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2021, worth a combined $1.31B — down 9.1% from $1.44B a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PMVP positions and 7 closed out — a net gain of 7 holders — while 34 added to existing stakes and 27 trimmed.

The largest buyer was Logos Global Management, adding an estimated $38.1M. The largest seller was Euclidean Capital, cutting an estimated $36.4M.

  • 92 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2021, up from 85 in Q2 2021.
  • Funds reported $1.31B of PMV Pharmaceuticals stock for Q3 2021, down 9.1% quarter-over-quarter.
  • 14 funds opened new PMV Pharmaceuticals positions in Q3 2021 and 7 closed out, a net change of +7 holders.
  • The largest PMV Pharmaceuticals buyer in Q3 2021 was Logos Global Management, an estimated $38.1M added.
  • The largest PMV Pharmaceuticals seller in Q3 2021 was Euclidean Capital, an estimated $36.4M sold.

Based on aggregated 13F filings for Q3 2021.